VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation by Milka Marinova et al.
PHARMACOKINETICS AND DISPOSITION
VKORC1-dependent pharmacokinetics of intravenous and oral
phylloquinone (vitamin K1) mixed micelles formulation
Milka Marinova & Dieter Lütjohann & Olof Breuer &
Heike Kölsch & Philipp Westhofen & Matthias Watzka &
Martin Mengel & Birgit Stoffel-Wagner &
Gunther Hartmann & Christoph Coch &
Johannes Oldenburg
Received: 8 June 2012 /Accepted: 13 July 2012 /Published online: 5 August 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Objective The pharmacokinetics of phylloquinone (vitamin
K1) were evaluated in healthy human adult volunteers (15
male and 15 female) following oral and intravenous admin-
istration of a mixed micelles formulation (Konakion® MM
2 mg) in an open label study design. The subjects were
allocated to one of three genotype-specific groups (n010
in each group) in terms of VKORC1 promoter polymor-
phism c.-1639 G>A to explore the relationship between
genotype and pharmacokinetic parameters.
Methods Blood samples were collected for up to 24 h after
administration. Phylloquinone serum levels were deter-
mined by reversed phase HPLC with fluorometric detection
after post-column zinc reduction. Pharmacokinetic evalua-
tion was performed using non-compartmental analysis.
Results Pharmacokinetic analysis of serum phylloquinone
concentration versus time profiles revealed significant dif-
ferences in the main pharmacokinetic parameters between
groups. Upon oral administration, VKORC1 AG carriers
showed 41 % higher mean bioavailability (p00.01) com-
pared with homozygous AA individuals. Furthermore, AG
subjects exhibited 30 % (p00.042) and 36 % (p00.021)
higher mean AUC compared with GG and AA respectively.
Terminal half-life was 32 % and 27 % longer for AG carriers
in comparison to GG (p00.004) and AA (p00.015) geno-
types respectively.
Conclusion Pharmacokinetic differences indicated signifi-
cant inter-individual variance of vitamin K fate in the human
body. The influence of the VKORC1 promoter polymor-
phism c.-1639 G>A on the pharmacokinetic properties of
phylloquinone could be demonstrated in humans. To gain
deeper insight in other potential genetic determinants of
systemic vitamin K exposure, further correlation of the
phenotype–genotype relationship of different players in vi-
tamin K turnover has to be gained.
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Clearance
Introduction
Vitamin K is a fat-soluble vitamin needed for a unique post-
translational chemical modification of proteins with
calcium-binding properties, collectively known as vitamin
K-dependent proteins (VKDPs) or Gla-proteins. Vitamin K
is mostly required for blood coagulation, but it is also
involved in metabolic pathways in bone and other tissue.
It acts as a cofactor in the synthesis of active blood-clotting
factors II, VII, IX, X, protein C and protein S as well as non-
coagulation proteins such as osteocalcin and matrix Gla
protein [1, 2]. Activation of VKDPs is linked to an enzy-
matic cycle, denoted the vitamin K cycle, which carries out
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both γ-glutamyl carboxylation of vitamin K and serves as a
salvage pathway to recover vitamin K from its epoxide
metabolite for reuse in carboxylation [3]. The latter reaction
is catalyzed by Vitamin K epoxide reductase (VKOR). In
2004, the gene encoding vitamin K epoxide reductase com-
plex subunit 1 (VKORC1), the key protein in the vitamin K
cycle, was identified and characterized [4, 5]. The activity of
the VKOR can be blocked by warfarin and other coumarin-
based drugs [6, 7]. Common polymorphisms such as
VKORC1 promoter polymorphism c.-1639 G>A and hap-
lotypes within the VKORC1 gene have been associated with
interindividual variability in the warfarin dose required for
therapeutic anticoagulation and show increased coumarin
sensitivity [8–12].
The major dietary form of vitamin K is phylloquinone
(vitamin K1), which is produced by green plants and present
in foods of plant origin, especially in green leaf and flower
vegetables [13]. Vitamin K is normally absorbed with other
fat-soluble vitamins predominantly from the proximal intes-
tine [14]. This intestinal absorption involves the solubiliza-
tion of vitamin K into mixed micelles composed of bile salts
and products of pancreatic lipolysis and is known to be
impaired in patients with malabsorption or other gastroin-
testinal disorders, including biliary atresia, cystic fibrosis,
celiac disease, and short bowel syndrome [15]. Vitamin K is
not known to have a carrier protein; instead, triglyceride-
rich lipoproteins (TRL), primarily chylomicron remnants
and very low-density lipoproteins (VLDL), are thought to
be the main transporters of phylloquinone [16–18]. Vitamin
K is extensively metabolized in the liver and excreted in the
urine (20 %) and bile (40 %).
There has been a recent interest in the role of genetics as a
determinant of the interindividual variation in vitamin K
status. Nongenetic determinants account for approximately
20 % of the interindividual variation in vitamin K status in
Caucasian adults [19]. Potential genetic determinants of
vitamin K status include variation in the genes involved in
transport or uptake of vitamin K into the tissue, thus influ-
encing tissue-specific availability. Moreover, vitamin K
recycling in the liver may be affected by polymorphisms
such as that of the aforementioned VKORC1 gene [8–10].
Further, polymorphisms in cytochrome P450 4 F2
(CYP4F2) and ATP-binding cassette sub-family C member
6 (ABCC6) genes have been linked to altered vitamin K
metabolism [20–22]. For instance, the presence of V433M
polymorphism (rs2108622) in CYP4F2 (haplotype
CYP4F2*3) caused elevated hepatic vitamin K1 levels,
necessitating a higher warfarin dose to reach therapeutic
anticoagulation response [20].
Examining different phenotype–genotype relationships
will elucidate the potential genetic determinants of the
vitamin K status. In this regard, the phenotype refers to
physiological processes such as absorption, distribution,
metabolism, and elimination of vitamin K. Therefore,
the primary aim of this phase I clinical study was to
explore the possible effect of the VKORC1 promoter
polymorphism c.−1639 G>A on the pharmacokinetics
of vitamin K1 in humans.
Materials and methods
Subjects and study design
The study was registered in the European Clinical Trials
Database (EudraCT number 2008-003643-36) and con-
ducted in accordance with Good Clinical Practice (GCP),
the current requirements of EMA (European Medicines
Agency) [23], the Declaration of Helsinki and local and
European law. The phase I study protocol was approved
by the Ethics Committee responsible (the Medical Faculty
of the Rheinische Friedrich-Wilhelms University Bonn) and
by the Federal Institute for Drugs and Medical Devices in
Germany (BfArM). Each volunteer participating in this
study was informed by the clinical investigator about the
modality and the possible risks of the trial and consented to
study participation in writing before undergoing the first
study-related procedure. Prior to and after the study treat-
ment, volunteers underwent safety clinical and laboratory
screening. Excluded from the study were: women of child-
bearing potential without reliable contraception, pregnant or
lactating women, persons with any disease likely to disturb
the vitamin K metabolism such as bleeding or thromboem-
bolic history (acute or persistent) or dysfunctions of intesti-
nal lipid absorption (Crohn’s disease, cholestatic liver
diseases).
Fifteen men (28±6 years, BMI 24±2 kg/ m2) and 15
women (29±7 years, BMI 21±2 kg/ m2) of Caucasian
origin, aged 22–46 years, participated in this study. Of these,
5 women and 5 men belonged to each VKORC1 genotype-
specific group [9] as described below. All subjects were
healthy according to their medical history, physical exami-
nation, and standard laboratory procedures. The subjects
refrained from any other medication from 10 days prior to
enrolment until the end of the study. Vitamin K1 was ad-
ministered as an investigational product in its synthesized
form phytomenadione, which is available as the liquid for-
mulation Konakion® MM containing 2 mg/200 μL in a
mixed micelles (MM) solution [24, 25]. Konakion® MM
2 mg is approved for prophylaxis and therapy of vitamin K
deficiency bleeding in newborns. In this clinical trial, vita-
min K1 pharmacokinetics was investigated in healthy vol-
unteers after oral and intravenous route of administration.
All participants were in a fasting state when Konakion®
MM was administered. Standardized food was served no
earlier than 10 h after dosing.
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A single oral dose of 2 mg Konakion® MM was followed
by a wash-out period of 7 days and a single intravenous
administration of the same dosage using an open label study
design. Pharmacokinetic parameters of the two routes of
administration were calculated and compared. The i.v. in-
jection was carried out into a vein of one forearm, opposite
to the one from which blood samples were taken. Systemic
and local tolerance of the investigational product were care-
fully checked by the clinical investigator. Blood samples
(7.5 mL each) were collected into serum gel tubes up to
24 h following p.o. and i.v. vitamin K1 administration: at 1,
2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 24 h after
p.o. dosing, and at 2, 5, 10, 20, 30, 40, 50 min, and 1, 1.5, 2,
2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, and 24 h after i.v.
injection. During the first 10 h, blood was collected through
a peripheral vein catheter. Serum was separated immediately
by centrifugation at 2,250 g for 10 min at 18°C and stored
protected from light at −20°C prior to analysis.
Genotyping
Confirmatory genotyping was performed to ensure that the
study subjects were equally distributed among the three
genotype groups of interest regarding VKORC1 :
c.−1639 G>A promoter polymorphism. Genotyping for
the SNP rs9923231 in the VKORC1 gene was performed
using a TaqMan® Allelic Discrimination Assay based on
fluorescence-labeled probes (primer and probe details as
described previously [26]). Subjects who were homozygous
GG carriers, heterozygous AG carriers as well as homozy-
gous AA genotypes were included (each group consisted of
5 men and 5 women). Within the Caucasian population, the
allele frequency is 43 % for the A allele and 57 % for the G
allele [9]. Furthermore, confirmatory genotyping was per-
formed retrospectively with regard to SNPs in the CYP4F2
(V433M polymorphism, C>T [20]) and ABCC6 (promoter
polymorphism c. −127 C>T [21, 22, 27]) genes involved in
vitamin K metabolism and elimination.
Analysis of vitamin K1 in serum
Vitamin K1 was determined by reversed phase HPLC com-
bined with fluorometric detection following post-column
zinc reduction as described previously [28]. Briefly, the
vitamin K related compounds were purified from serum by
liquid–liquid extraction using n-hexane. After the addition
of the appropriate amount of internal standard (0.5, 1 or 2 ng
per absolute injection), the upper hexane layer was quanti-
tatively collected, pooled, and evaporated to dryness under a
gentle stream of nitrogen at 50°C. Vitamin K isolation from
lipid extracts was performed by using a solid phase extrac-
tion (SPE) system. The separated and dried vitamin K
fraction was dissolved in 50 μL of 2-propanol and subjected
to HPLC analysis. Vitamin K compounds, all in the nonflu-
orescent quinone forms, were separated by an isocratic
HPLC system on a reversed phase-C18 column and then
converted to their fluorescent hydroquinone forms by post-
column zinc reduction. The mobile phase contained, per
liter, 880 mL of methanol, 100 mL of acetonitrile, 1.1 g of
zinc acetate, 10 mL of acetic acid, and 10 mL of water. The
flow rate was 0.8 mL/ min and the detection wavelengths
were 246 nm excitation, 430 nm emission. The limits of
detection and quantification were 0.015 ng mL−1 and
0.15 ng mL−1 respectively. High sensitivity, analytical re-
coveries, accuracy, and calibration curve linearities could be
reached, as shown before [28]. The within-day and day-to-
day coefficients of variation amounted to less than 10 %,
while the recovery ranged from 91 % to 114 %. The accu-
racy was proven by good results from external quality
assurance [29]. Long-term stability was verified over a
period of 6 months.
Instrumentation, reagents, disposables, and standards
The isocratic HPLC system (VWR, Darmstadt, Germany)
consisted of separation Hitachi modules with an in-line
vacuum degasser, an L-2130 pump, an L-2200 autosampler,
an L-2300 column oven, and an L-2485 fluorescence detec-
tor, all controlled by Elite LaChrom software (V.3.1.7.). A
Nucleodur C18 Gravity column (3 mm i.d. × 100 mm in
length, 3-μm particle size) was used for separation. The
lipid compounds were separated using a solid-phase extrac-
tion vacuum manifold. The analytical reagent grade chem-
ical zinc acetate (99.99 % metallic basis) was obtained from
Sigma–Aldrich (Hamburg, Germany). Acetic acid for vita-
min K determination assay was purchased from VWR In-
ternational (Darmstadt, Germany). All solvents used were
HPLC grade (LiChrosolv®) and obtained from VWR
(Darmstadt, Germany). Disposable SPE Cartridges Chroma-
bond®SiOH 3 mL/ 500 mg were supplied by Macherey-
Nagel (Düren, Germany). Vitamin K, i.e., phylloquinone
and menaquinone-4, with a purity of 99 % were purchased
from Sigma–Aldrich (Hamburg, Germany). The internal
standard (ISTD) vitamin K1(25) [30] as a 10-mg/mL solu-
tion was kindly provided by Dr. Schurgers, University of
Maastricht, the Netherlands. Konakion® MM 2 mg was
purchased from Roche (Grenzach-Wyhlen, Germany).
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters were determined for each subject
using noncompartmental analysis with WinNonlin (version
5.2.1., Pharsight Corp., CA, USA). Serum concentration –
time data of vitamin K1 was considered the primary variable
as well as the evaluation of pharmacokinetic parameters in-
cluding maximum serum concentration (Cmax), time of the
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maximum serum concentration (tmax), area under the curve
from time zero to infinity (AUC), bioavailability (Fp.o.), clear-
ance (CL), volume of distribution at steady state (Vss), termi-
nal half-life (t½).
AUC was calculated by AUC0AUC0-t+Clast / λz using
the linear–log trapezoidal method. The terminal (first-order)
elimination rate constant (λz) was calculated from the slope
of the terminal linear portion of the log concentration vs
time curve by linear regression analysis. The mean resi-
dence time (MRT) was calculated as AUMC/AUC where
AUMC is the area under the first moment curve. Vss was
calculated as: Vss0MRT × CL. The Fp.o. of Konakion® MM
was calculated as: Fp.o. 0 AUC p.o. / AUC i.v. × Dose i.v. /
Dose p.o. x 100 % . The systemic CL was calculated accord-
ing to the equation: CL0Dose i.v. / AUC i.v..
t½ was calculated using the terminal elimination rate
constant as: t½00.693/ λz.
The plasma concentration values were corrected for en-
dogenous vitamin K levels in each subject by the subtraction
of individual pre-dose values from all post-dose values. The
plasma concentration was set to zero in instances where
such correction resulted in small negative values.
Linear regression, mean, median, standard deviation
(SD), and standard error of the mean (SEM) were calculated
using Microsoft Excel. Statistical evaluation was performed
using SPSS (IBM SPSS Statistics 19.0). Univariate analyses
of variance (uANOVA) were performed including gender as
a factor and Tukey post-hoc testing. Thus, significance
differences in various pharmacokinetic parameters, such as
Fp.o., t½, AUC etc., could be proven.
Results
Thirty healthy volunteers were included in the clinical study
on the pharmacokinetics of vitamin K1. Baseline character-
istics were balanced across VKORC1 genotype groups. The
plasma concentration–time profiles of vitamin K1 were
obtained by HPLC-RP18 with fluorescence detection. All
evaluated pharmacokinetic parameters obtained by noncom-
partmental analysis were normally distributed. Pharmacoki-
netic data for each genotype GG, AG, and AA VKORC1:c.-
1639 G>A are summarized in Table 1. Some of the main
parameters, such as Cmax and tmax, were estimated directly
from the data. Figure 1 represents mean vitamin K1 serum
concentrations (n010 for each time point), expressed on a
logarithmic scale, vs time profiles, obtained after p.o. intake of
2 mg Konakion®MM and following i.v. administration of the
same dosage for each VKORC1 group (Fig. 1a regarding GG,
Fig. 1b AG, and Fig. 1c AA). Phylloquinone concentration–
time curves varied between the volunteers as well as when p.o.
and i.v. experiments were compared, although the general
curve shape following each route of administration remained
similar. The i.v. plasma concentration–time curves showed a
Table 1 Differences in vitamin
K1 pharmacokinetic parameters
between VKORC1: c.−1639 G>
A groups (uANOVA with regard
to gender)
*p<0.05; significantly different
from GG (Post-hoc with Tukey)
§p<0.05; significantly different
from AA (Post-hoc with Tukey)
$p<0.01; significantly different
from GG (Post-hoc with Tukey)
aClearance following oral (p.o.)
administration CL/F
bMean values ± standard devia-
tion with range in parenthesis;
n010 in each group




b 210±119 217±132 n.s.
(120–362) (119–481) (122–542)
Cmax (ng mL
-1) 29±11 30±10 27±12 n.s.
(15–55) (14–44) (6–46)
AUC (ng hmL-1) 145±68 206±79*, § 132±50 0.015
(94–278) (92–364) (45–211)
Fp.o. (%) 51±20 73±33
§ 43±13 0.011
(23–90) (38–150) (27–70)
CLa (mL min-1) 253±80 165±76 286±160 n.s.
(116–331) (72–338) (154–679)
t½ (min) 311±54 457±141
$, § 332±48 0.003
(250–394) (313–787) (261–429)
i.v.
AUC (ng hmL-1) 298±97 318±48 319±78 n.s.
(204–510) (238–390) (177–453)
Vss (L) 23±8 25±13 19±5 n.s.
(11–35) (10–58) (12–27)
CL (mL min-1) 118±32 104±19 109±33 n.s.
(64–164) (70–136) (71–187)
t½ (min) 436±186 492±385 383±114 n.s.
(133–727) (194–1543) (158–548)
470 Eur J Clin Pharmacol (2013) 69:467–475
biexponential decline, suggesting a short initial distribution
phase followed by an elimination phase. The curves obtained
after the p.o. route of administration showed an initial absorp-
tion phase with a roughly monoexponential decay after Cmax
was reached. However, there was also a second and a third
distinct maximum following Cmax, which is typical for sub-
stances undergoing enterohepatic circulation.
Following oral vitamin K1 administration, pharmacoki-
netic parameters such as AUC, Fp.o., and t½ showed statis-
tically significant differences between the VKORC1
genotype groups (uANOVA model; corresponding p values
are listed in Table 1). AG subjects exhibited 30 % (p00.042)
and 36 % (p00.021) higher mean AUC compared with GG
and AA individuals respectively. The mean bioavailability
for AG carriers was 41 % higher (p00.01; Fig. 2) than for
homozygous AA individuals. Statistically significant differ-
ences in terminal half-life between groups were also ob-
served. AG genotype carriers showed 32 % and 27 %
longer t½ to GG (p00.004) and AA (p00.015) genotype
carriers respectively. Furthermore, the bioavailability was
on average significantly higher for men than for women
(66 % vs 45 % respectively; p00.024).
Interestingly, statistically significant differences in bio-
availability (Fig. 2) and terminal half-life (Fig. 3) were also
found when the results from both groups of homozygous
individuals (GG+AA) were pooled and compared with
those of heterozygous subjects (AG). In addition, homozy-
gote carriers of the A-allele showed lower Fp.o. mean values
than GG+AG genotype carriers (Fig. 2), whereas homozy-
gous carriers of the G-allele exhibited shorter t½ than car-
riers of at least one A allele (AG+AA) (Fig. 3).
Following intravenous vitamin K1 administration, statis-
tically significant differences between VKORC1 genotype
groups were not observed for pharmacokinetic parameters
AUC, Vss, CL, and t½ by application of uANOVA analysis
(mean values shown in Table 1).
To investigate the role of polymorphisms of other genes
such as CYP4F2 and ABCC6 on vitamin K pharmacokinet-
ics, differences in main pharmacokinetic parameters were
assessed in relation to these genotypes (Table 2). For both
CYP4F2 and ABCC6, two groups were selected: one group
Fig. 1 Serum concentration (log scale) vs time profiles of vitamin K1
for each VKORC1 group (VKORC1 promoter polymorphism c.
−1639 G>A) following p.o. and i.v. administration. a Group GG, b
Group AG, c Group AA
Fig. 2 Significant differences (uANOVA) in bioavailability among
VKORC1 groups (AG to AA; AG to GG + AA; AA to GG + AG)
following vitamin K1 p.o. administration
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of homozygous wild-type carriers CC and one group of
individuals with at least one T allele (CT+TT). This was
due to the very small number of TT carriers (n01 for
CYP4F2 and n01 for ABCC6). For the V433M polymor-
phism of the CYP4F2 gene, mean Vss values differed sig-
nificantly between the two groups (uANOVA; p00.036) and
were lower for the wild-type individuals. Between ABCC6
genotypes considerable differences in i.v. Vss mean values
were also observed (uANOVA; p00.031), in that Vss values
were lower for the wild-type group (CC genotype).
Correlation analysis between vitamin K1 pharmacokinet-
ic parameters and fasting plasma triglycerides was per-
formed without stratification for VKORC1 genotypes. For
each route of phylloquinone administration (p.o. and i.v),
triglyceride levels inversely correlated significantly with CL
(p<0.05), showing Pearson product–moment correlation
coefficients of about −0.4 (data not shown).
Discussion
The present exploratory phase I clinical study was designed to
determine inter-individual pharmacokinetic variance of vita-
min K fate in the human body. Furthermore, the possible effect
of the VKORC1 promoter polymorphism c. −1639 G>A on
the metabolism of phylloquinone, by means of correlating
pharmacokinetic properties with the different genotypes in
Fig. 3 Significant differences (uANOVA) in elimination half-time
among VKORC1 groups (AG + AA to GG; GG + AA to AG)




CYP4F2*3) and ABCC6 (pro-
moter polymorphism c. −127
C>T) group CC and group CT +
TT
*p<0.05; significantly different
from CT + TT ABCC6;
uANOVA (with regard to
gender)
aClearance following oral (p.o.)
administration CL/F
bMean values ± standard devia-
tion with range in parenthesis
Pharmacokinetics parameter CYP4F2 ABCC6
CC CT + TT CC CT + TT
(n020) (n010) (n021) (n09)
p.o.
tmax (min) 209±111
b 190±104 211±120 184±69
(119–542) (122–481) (119–542) (122–360)
Cmax (ng mL
-1) 29±13 29±8 29±13 28±6
(6–55) (14–38) (6–55) (20–38)
AUC (ng hmL-1) 160±82 163±51 154±81 176±49
(45–364) (96–262) (45–364) (106–262)
Fp.o. (%) 56±30 54±17 52±28 63±19
(23–150) (32–90) (23–150) (32–92)
CLa (mL min-1) 248±138 208±69 255±133 187±66
(72–679) (116–331) (72–679) (116–307)
t½ (min) 366±126 367±74 349±76 409±164
(250–787) (285–524) (250–592) (259–787)
i.v.
AUC (ng hmL-1) 310±81 322±63 315±78 303±71
(177–510) (219–390) (177–510) (204–390)
Vss (L) 20±6* 27±13 20±6* 28±13
(10–35) (12–58) (11–33) (10–58)
CL (mL min-1) 112±30 106±25 110±28 112±31
(64–187) (70–148) (64–187) (70–164)
t½ (min) 386±135 539±383 402±120 519±425
(133–707) (158–1,543) (194–707) (133–1,543)
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humans was investigated. There are only a few reports about
the pharmacokinetics of vitamin K after oral, intravenous or
intramuscular single-dose administration [31–35]. The inves-
tigation was performed in a representative group of healthy
volunteers. The trial showed a statistically significant differ-
ence in bioavailability after oral administration of phylloqui-
none among VKORC1 genotype groups (particularly by
comparison of AG individuals with AA carriers). Fp.o. values
were in accordance with data from previous studies [28] and
revealed substantial inter-individual variability. It is notewor-
thy that the highest bioavailability was found in heterozy-
gotes, carriers of the AG genotype; furthermore, it was
higher for male than for female subjects, although this finding
cannot be physiologically and clinically eligible. Vitamin K is
mostly required for blood coagulation, but is also involved in
metabolic pathways in bone and other tissue. In view of the
multifunctional role of this vitamin in the human body, an
evolutionary enrichment in individuals in the population with
the potential for high vitamin K exposure seems reasonable.
However, the mechanism by which the VKORC1 AG geno-
type yields the highest bioavailability compared with the other
polymorphisms remains to be elucidated. Moreover, it must
be noted that AA genotype carriers showed the lowest phyl-
loquinone bioavailability. This fact could play a role, for
instance, when vitamin K adjustment in unstable patients
under warfarin therapy is required, or when vitamin K has to
be supplemented orally to antagonize intoxication with roden-
ticides or is given to over-anticoagulated patients therapeuti-
cally. However, the safest approach to giving vitamin K to
patients remains high-dose administration without gene dose
adjustment.
Considering retrospectively other genes involved in vita-
min K metabolism and tissue distribution, such as CYP4F2
and ABCC6 polymorphisms, a considerable difference in
intravenous Vss between phenotypes was shown, whereas
other pharmacokinetic parameters do not seem to be influ-
enced. However, to obtain a deeper insight into such a
relationship further investigations with more subjects are
needed. Because of the small number of homozygous poly-
morphism carriers, possible differences among the three
groups could not be distinguished, perhaps missing a poten-
tial distinction in pharmacokinetics.
Terminal half-lives following oral phylloquinone admin-
istration were considerably longer for VKORC1 heterozy-
gotes than for the homozygous carriers. This observation
also remained valid after pooling both homozygous groups,
GG and AA genotypes, together and comparing them with
the AG genotype carriers. The terminal half-lives showed
larger variation following intravenous administration than
those following oral dosing. Hence, there was a tendency,
albeit not a statistically significant one, toward longer half-
lives in VKORC1 heterozygotes also following intravenous
administration. The estimated mean terminal half-lives of
6.1 h after oral phylloquinone administration were compa-
rable with previously published data [31]. In contrast, the
mean terminal half-life of 7.3 h following intravenous ad-
ministration was longer than in previous data, but can be
explained by one subject showing an extremely long value.
It should be noted that all observed significant differences
between groups remain valid, even after exclusion of this
individual from the analysis.
The plasma concentration–time profiles in most subjects
showed at least two additional peaks during the elimination
phase following oral dosing. This is sometimes seen with
compounds undergoing enterohepatic circulation, but
appears unlikely in this case since straight exponential
declines were seen after intravenous administration. It is
also noteworthy that the absorption was rather slow, so that
mean Cmax was not reached before 3 h. Hence, the most
likely explanation for multiple peaks with oral dosing is
absorption dependence on food or emptying of bile acids.
This is further corroborated by that fact that extra peaks
were in synchrony in most subjects, and occurred at time
points following each meal intake. Moreover, as a conse-
quence of a protracted absorption phase, plasma concentra-
tions at late time points were higher following oral
administration than those after intravenous dosing.
The liver is the primary eliminating organ, as is evident
from previously published studies in patients with severe
acute liver disease, where phylloquinone serum half-lives
were approximately twice as long as those found in subjects
with normal hepatic function [34]. Moreover, terminal half-
lives of vitamin K1 in newborns were also considerably
longer compared with adults [33]. Based on our findings,
it can be suggested that the highest phylloquinone bioavail-
ability in VKORC1 heterozygotes can be aligned with lower
clearance and the potential for higher systemic exposure to
vitamin K in these subjects. Furthermore, provided that
hepatic metabolism is the major route of elimination, lower
clearance indicates lower hepatic uptake and/or vitamin K
metabolism in VKORC1 AG genotype carriers. Theoreti-
cally, differences in body composition (fatty tissue) and
transporting triglyceride-enriched lipoproteins (VLDL) [17,
36] could affect tissue distribution and elimination rates for
a lipid-soluble compound such as vitamin K. However, in
this study there were no significant differences in Vss be-
tween groups, and inclusion of plasma triglyceride levels as
a potential influencing factor in uANOVA did not diminish
the significance of differences in Fp.o. between groups.
In conclusion, significant inter-individual pharmacokinetic
variance of vitamin K fate in the human body could be
indicated. Further, an influence of the VKORC1 promoter
polymorphism c. −1639 G>A on the pharmacokinetic prop-
erties of phylloquinone in humans was shown. Significant
differences in main pharmacokinetic parameters, such as bio-
availability and terminal half-life between groups, suggest
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corresponding differences in the processing of vitamin K in
the human body. The clinical importance of potential genetic
determinants of vitamin K status should be further investigat-
ed with respect to effects on absorption, distribution, metabo-
lism, and elimination of vitamin K.
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